J
Jean-Jacques Body
Researcher at Université libre de Bruxelles
Publications - 397
Citations - 21506
Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Paul A C Cloos,C. Fledelius,Stephan Christgau,Claus Christiansen,M. Engsig,Pierre D. Delmas,Jean-Jacques Body,Patrick Garnero +7 more
TL;DR: The study suggests that in conditions with a localized alteration in bone turnover the ratio between aL CTX and the age-modified forms is significantly elevated, which may provide a new diagnostic and monitoring tool for diseases such as metastatic bone cancer and Paget's disease.
Journal ArticleDOI
"Nonspecific" increases in plasma immunoreactive calcitonin in healthy individuals: discrimination from medullary thyroid carcinoma by a new extraction technique.
Jean-Jacques Body,Hunter Heath +1 more
TL;DR: The occasional factor in plasma of healthy persons that interferes in assays for CT is eliminated by the silica extraction method, and in this way such cases can be distinguished from cases of medullary thyroid carcinoma.
Journal ArticleDOI
Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
Evelien Gielen,Pierre Bergmann,Olivier Bruyère,Etienne Cavalier,Pierre Delanaye,Stefan Goemaere,Jean-Marc Kaufman,Médéa Locquet,Jean-Yves Reginster,Serge Rozenberg,A.-M. Vandenbroucke,Jean-Jacques Body +11 more
TL;DR: There is an urgent need to appreciate bone loss associated with anorexia nervosa, patients on dialysis, cancer patients, persons with sarcopenia, and the oldest old, as this may improve diagnosis and management of bone loss and fracture risk in clinical practice.
Journal ArticleDOI
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features— An exploratory analysis of placebo-controlled trials
Robert E. Coleman,Allan Lipton,Luis Costa,Richard J. Cook,Ker Ai Lee,Fred Saad,Janet E. Brown,Evangelos Terpos,Pierre Major,Norio Kohno,Matthew R. Smith,Jean-Jacques Body +11 more
TL;DR: Although OS was similar between the overall treatment groups, ZOL significantly improved OS in the subset of patients with elevated baseline NTX, independent of SRE prevention.
Journal ArticleDOI
Breast Cancer Cells Release Factors That Induce Apoptosis in Human Bone Marrow Stromal Cells
TL;DR: FasLigand secreted by BCCs induces apoptosis and necrosis of human preosteoblastic stromal cells through caspase cascade modulated by the bax and bcl‐2 protein level, which may contribute to the inappropriately low osteoblast reaction and bone formation during tumor‐induced osteolysis in bone metastases.